首页|A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine
A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
Sars Cov-2， the pathogen which belongs to the beta coronavirus family that is responsible for COVID-19， uses Angiotensin Converting Enzyme 2 (ACE2) as a receptor， which is responsible for controlling the actions of reninangiotensin system (RAS)。 Sars Cov-2 - ACE2 binding leads to a RAS mediated immune response， which targets especially lungs to form ARDS， which in turn， is the most important cause of mortality in COVID-19。 CD8+ T cell response dominates over CD4+ T cell response and natural killer cell dysfunction also leads to CD4+ cell dysfunction in COVID-19; this immune dysregulation leads to inappropriate (ARDS) and inadequate (low or quickly waning antibodies) responses to the disease and unfortunately， prepares the patients for re-infections。 The peripheral anergy seen in chronic sarcoidosis has much resemblance to COVID-19; CD8+ T cell accumulation is also responsible for inadequate reaction to tuberculin and antigenic stimulus。 This article， based on the similarity of COVID-19 and sarcoidosis， discusses a combination of the therapeutic strategy of the tetanusdiphtheria vaccine and dual RAS inhibition， alongside with hydroxychloroquine and antiviral agents， as a solution to overcome the problems described above。
NSTL
Elsevier
